EP0639226A4 - Procede de traitement de leucemies. - Google Patents

Procede de traitement de leucemies.

Info

Publication number
EP0639226A4
EP0639226A4 EP19910912361 EP91912361A EP0639226A4 EP 0639226 A4 EP0639226 A4 EP 0639226A4 EP 19910912361 EP19910912361 EP 19910912361 EP 91912361 A EP91912361 A EP 91912361A EP 0639226 A4 EP0639226 A4 EP 0639226A4
Authority
EP
European Patent Office
Prior art keywords
treating leukemias
leukemias
treating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP19910912361
Other languages
German (de)
English (en)
Other versions
EP0639226A1 (fr
Inventor
Premkumar Reddy
Scott Shore
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wistar Institute of Anatomy and Biology
Original Assignee
Wistar Institute of Anatomy and Biology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wistar Institute of Anatomy and Biology filed Critical Wistar Institute of Anatomy and Biology
Publication of EP0639226A4 publication Critical patent/EP0639226A4/fr
Publication of EP0639226A1 publication Critical patent/EP0639226A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/111—Antisense spanning the whole gene, or a large part of it
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
    • C12N2310/121—Hammerhead
EP91912361A 1990-06-26 1991-06-25 Molecule d'arn pour utilisation dans le traitement de leucemies Withdrawn EP0639226A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US54419990A 1990-06-26 1990-06-26
US544199 1990-06-26
PCT/US1991/004545 WO1992000080A1 (fr) 1990-06-26 1991-06-25 Procede de traitement de leucemies

Publications (2)

Publication Number Publication Date
EP0639226A4 true EP0639226A4 (fr) 1993-11-11
EP0639226A1 EP0639226A1 (fr) 1995-02-22

Family

ID=24171171

Family Applications (1)

Application Number Title Priority Date Filing Date
EP91912361A Withdrawn EP0639226A1 (fr) 1990-06-26 1991-06-25 Molecule d'arn pour utilisation dans le traitement de leucemies

Country Status (3)

Country Link
EP (1) EP0639226A1 (fr)
CA (1) CA2086105A1 (fr)
WO (1) WO1992000080A1 (fr)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5246921A (en) * 1990-06-26 1993-09-21 The Wistar Institute Of Anatomy And Biology Method for treating leukemias
EP0551294A4 (en) * 1991-08-01 1993-12-29 City Of Hope Ribozyme inhibition of bcr-abl gene expression
US5496698A (en) * 1992-08-26 1996-03-05 Ribozyme Pharmaceuticals, Inc. Method of isolating ribozyme targets
AU687001B2 (en) * 1992-05-14 1998-02-19 Ribozyme Pharmaceuticals, Inc. Method and reagent for inhibiting cancer development
US6492512B1 (en) 1992-08-26 2002-12-10 Ribozyme Pharmaceuticals, Inc. Method and reagent for treatment of lung cancer and other malignancies caused by the deregulation of L-MYC gene expression
US5750390A (en) * 1992-08-26 1998-05-12 Ribozyme Pharmaceuticals, Inc. Method and reagent for treatment of diseases caused by expression of the bcl-2 gene
US5610052A (en) * 1992-08-26 1997-03-11 Ribozyme Pharmaceuticals Inc. Enzymatic RNA with activity to ras
US6544755B1 (en) 1992-08-26 2003-04-08 Ribozyme Pharmaceuticals, Inc. Method and reagent for treatment of diseases by expression of the c-Myc gene
US5646042A (en) * 1992-08-26 1997-07-08 Ribozyme Pharmaceuticals, Inc. C-myb targeted ribozymes
US5599704A (en) * 1992-08-26 1997-02-04 Ribozyme Pharmaceuticals, Inc. ErbB2/neu targeted ribozymes
JPH08506724A (ja) * 1992-12-04 1996-07-23 アポロン・インコーポレーテッド 白血病治療のための化合物および方法
US5811300A (en) * 1992-12-07 1998-09-22 Ribozyme Pharmaceuticals, Inc. TNF-α ribozymes
US5658780A (en) 1992-12-07 1997-08-19 Ribozyme Pharmaceuticals, Inc. Rel a targeted ribozymes
US5616490A (en) * 1992-12-07 1997-04-01 Ribozyme Pharmaceuticals, Inc. Ribozymes targeted to TNF-α RNA
US5612215A (en) * 1992-12-07 1997-03-18 Ribozyme Pharmaceuticals, Inc. Stromelysin targeted ribozymes
US5837542A (en) * 1992-12-07 1998-11-17 Ribozyme Pharmaceuticals, Inc. Intercellular adhesion molecule-1 (ICAM-1) ribozymes
US5616488A (en) * 1992-12-07 1997-04-01 Ribozyme Pharmaceuticals, Inc. IL-5 targeted ribozymes
US5639655A (en) * 1993-01-19 1997-06-17 Ribozyme Pharmaceuticals, Inc. PML-RARA targeted ribozymes
US5635385A (en) * 1993-09-15 1997-06-03 Temple University-Of The Commonwealth System Of Higher Education Multi-unit ribozyme inhibition of oncogene gene expression
US20020081733A1 (en) * 1995-11-14 2002-06-27 Catherine M. Verfaillie Method to prepare drug-resistant, non-malignant hematopoietic cells

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0640688A1 (fr) * 1987-12-15 1995-03-01 Gene Shears Pty. Limited Ribozymes
US4874853A (en) * 1988-04-18 1989-10-17 City Of Hope Synthetic oligonucleotides useful in diagnosis of chronic myelogenous leukemia

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
SCIENCE vol. 245, 8 September 1989, LANCASTER, PA US pages 1107 - 1110 CARACCIOLO, D. ET AL. 'Lineage-specific requirement of c-abl function in normal hematopoiesis' *
See also references of WO9200080A1 *

Also Published As

Publication number Publication date
CA2086105A1 (fr) 1991-12-27
WO1992000080A1 (fr) 1992-01-09
EP0639226A1 (fr) 1995-02-22

Similar Documents

Publication Publication Date Title
EG19392A (en) Improved method for omprazole symthesis
EP0639226A4 (fr) Procede de traitement de leucemies.
HK1011784A1 (en) Character processing method
EP0528869A4 (fr) Procede de traitement d'une paroi arterielle lesee lors d'une angioplastie.
EP0657656A3 (fr) Système hydraulique.
EP0601812A3 (en) An anatomical process.
GB2251403B (en) Degreasing-cleaning method
EP0492335A3 (en) Method for surface treatment
GB2243839B (en) Apparatus for treating bearings
EP0578138A3 (fr) Méthode pour la détection de gènes.
EP0461811A3 (en) Pattern processing method
EG19841A (en) Method for treating respiratory dissorders
EP0469915A3 (en) Figure processing method
EP0469918A3 (en) Figure processing method
EP0469914A3 (en) Figure processing method
EP0649408A4 (fr) Procede de production de phenylthiomethylpyridinylalcenoates.
ZA925912B (en) Defaunation method.
GR3018723T3 (en) Composting apparatus.
EP0547225A4 (fr) Procede d'edition de formes.
RU1785687C (ru) Cпocoб лeчehия глoccaлгии
GB9000899D0 (en) Nodularlising method
GB8912239D0 (en) Treating method
SG117493G (en) Apparatus for treating strip-chaped elements.
GB9025593D0 (en) Treatment method
GB9025594D0 (en) Treatment method

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19930108

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IT LI LU NL SE

17Q First examination report despatched

Effective date: 19951013

GRAG Despatch of communication of intention to grant

Free format text: ORIGINAL CODE: EPIDOS AGRA

GRAH Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOS IGRA

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 19970609